Research programme: prophylactic Chlamydia trachomatis vaccines - Genocea Biosciences

Drug Profile

Research programme: prophylactic Chlamydia trachomatis vaccines - Genocea Biosciences

Alternative Names: Chlamydia vaccines - Genocea Biosciences; CT 144; CT 823; GEN-001; GENO 001

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Genocea Biosciences; Harvard Medical School
  • Developer Genocea Biosciences
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chlamydial infections

Most Recent Events

  • 06 May 2015 Genocea plans to file an IND application for Chlamydial infections (Genocea Biosciences 10-K, May 2015)
  • 05 Dec 2013 Preclinical development is ongoing in USA
  • 06 Sep 2013 Isconova is now called Novavax AB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top